Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on June 9, 2016, to report the entry into a material definitive agreement. The company is incorporated in Delaware and maintains its principal executive offices in La Jolla, California.
Key Financial Metrics
This filing does not provide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific contractual agreement.
Material Changes
On June 9, 2016, the Company entered into a second amendment to its sublease with Wellspring Biosciences LLC, originally dated August 29, 2014. The primary material change is the extension of the sublease term from August 30, 2016, to October 31, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely to disclose the amendment of the Wellspring sublease agreement.
Investor Verification Points
- Verify the full text of the Wellspring Amendment, which is expected to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2016.
- Confirm the specific financial terms and obligations associated with the extended sublease period through October 31, 2019.